

Si invia in allegato la comunicazione relativa alla carenza temporanea/distribuzione contingentata sul mercato del medicinale Pergoveris (450 UI + 225 UI)/0,72 mL soluzione iniettabile in penna preriempita (AIC: 038085054/E).

Distinti saluti  
Silvia Novelli

Silvia Novelli Ph.D.  
Regulatory Affairs Specialist  
Biopharma | Global Regulatory Affairs & Quality Assurance

## Merck

Merck Serono S.p.A. | Via Casilina 125 | 00176 Rome | Italy

Mobile: +393427563605

E-mail: [silvia.novelli@merckgroup.com](mailto:silvia.novelli@merckgroup.com)

Mandatory information can be found at: <http://www.merckgroup.com/mandatories>

Informazioni obbligatorie consultabili su: <http://www.merckgroup.com/mandatories>

This message and any attachment are confidential and may be privileged or otherwise protected from disclosure. If you are not the intended recipient, you must not copy this message or attachment or disclose the contents to any other person. If you have received this transmission in error, please notify the sender immediately and delete the message and any attachment from your system. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not accept liability for any omissions or errors in this message which may arise as a result of E-Mail-transmission or for damages resulting from any unauthorized changes of the content of this message and any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not guarantee that this message is free of viruses and does not accept liability for any damages caused by any virus transmitted therewith.

Click [merckgroup.com/disclaimer](https://merckgroup.com/disclaimer) to access the German, French, Spanish, Portuguese, Turkish, Polish and Slovak versions of this disclaimer.

Please find our Privacy Statement information by clicking here: [merckgroup.com/privacy-statements-by-location](https://merckgroup.com/privacy-statements-by-location)

**MODELLO DI COMUNICAZIONE CARENZE TEMPORANEE FARMACI**

<b>AIC PRODOTTO</b>	038085054/E
<b>NOME COMMERCIALE</b>	PERGOVERIS
<b>DOSAGGIO E FORMA FARMACEUTICA</b>	(450 UI + 225 UI)/0,72 Ml soluzione iniettabile in penna preriempita
<b>PERIODO PRESUMIBILE DI CARENZA</b>	<b>dal 07/04/2023</b>
<b>DATA PRESUNTA RIPRISTINO REGOLARI FORNITURE</b>	<b>al 26/04/2023</b>
<b>ALTRE INFORMAZIONI</b>	Come da nota AIFA sulla lista farmaci attualmente carenti aggiornata al 07/04/2023:  “medicinale disponibile ma in distribuzione contingentata; dal Titolare AIC saranno evasi gli ordini necessari per garantire la continuità terapeutica ai pazienti ma non per scorte di reparto”.